GlucoTrack sets 1-for-2 reverse split, raises $2M via secured convertible notes
GlucoTrack will combine shares 1-for-2 on October 26 and closed a $2 million private placement of notes and warrants on October 22, 2026.
GlucoTrack, Inc. announced on October 22, 2026 that it will carry out a 1-for-2 reverse stock split of its common stock, effective with the opening of trading on Monday, October 26, 20261. The company said its stock will keep trading on Nasdaq under the ticker GCTK, with a new CUSIP number of 45824Q879, and that the number of total outstanding shares of common stock will be proportionally reduced from 2,368,237 shares to approximately 1,184,119 shares1.
The company said the split is meant to help it regain compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) and to make the prevailing price of its common stock more attractive to a broader group of institutional investors1. Under a Nasdaq Hearings Panel exception, the company must maintain a closing bid price of at least $1.00 for each trading day until November 9, 20261.
Separately, on October 22, 2026, GlucoTrack entered a securities purchase agreement issuing senior secured convertible notes in the aggregate principal amount of $2,564,102.65 for an aggregate cash purchase price of $2,000,000, reflecting a 22% original issue discount1. The notes bear interest at a rate of 8% per annum on the outstanding principal amount and mature nine months after their issuance on October 22, 20261, with default interest rising to 18% per annum until paid in full1. The financing closed the same day, resulting in gross proceeds to the company of $2,000,000, before deducting the placement agent's fees and other offering expenses1.
GlucoTrack also issued warrants to purchase 8,025,360 shares of common stock, representing a number of shares equal to 200% of each investor's principal amount under its note divided by $0.63901, exercisable for five years at $1.5975 per share. Dawson James Securities, Inc. acted as placement agent, entering a Placement Agency Agreement and earning a 7% cash fee plus warrants to purchase 160,508 shares1.
The filing was signed by Chief Executive Officer Erik Emerson on October 22, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.